Drug
CC 122
CC 122: highest development phase Phase 1, developed by Bristol-Myers Squibb. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Bristol-Myers Squibb
Trials
| Drug | Phase | Indication |
|---|---|---|
| CC-122 NCT05688475 | Phase 1 | Non-Hodgkin Lymphoma |
Latest
No recent events.
Follow CC 122 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.